Adjusted Multi-Biomarker Immunoassay Scoring for RA Activity Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current clinical assessments for rheumatoid arthritis (RA) are subjective, invasive, time-consuming, and lack specificity, while biomarker-based tests face challenges due to non-specific matrix binding and interference from rheumatoid factor, limiting their effectiveness in accurately assessing disease activity and predicting future outcomes.
Innovation Solution
A method using immunoassays to generate scores based on quantitative data for specific protein biomarkers, adjusted by clinical variables such as age, gender, and adiposity, to provide a more objective and predictive disease activity score for RA, incorporating a multiplex assay to detect multiple biomarkers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional clinical assessments (DAS, CDAI, SDAI) are used to evaluate RA disease activity, then disease activity can be monitored, but the assessments are subjective, invasive, time-consuming, and lack specificity
Solution Approach 1:
The patent replaces manual clinical assessments (physical examinations, subjective patient reports) with an automated immunoassay system that measures biomarker levels in blood samples. The system uses robotic liquid handling, automated plate readers, and software algorithms to calculate disease activity scores, eliminating the need for physician physical exams and patient subjective reporting while improving precision through objective biomarker measurements.
Solution Approach 2:
The system enables self-service through automated sample processing where the immunoassay system automatically performs all steps from sample preparation to result generation without requiring skilled operators. The automated algorithm calculates disease activity scores directly from biomarker measurements, allowing the system to serve itself and reducing dependence on clinician expertise and time.
2Measurement precision
If biomarker-based tests are used to assess disease activity, then objective measurements can be obtained, but non-specific matrix binding and rheumatoid factor interference limit effectiveness
Solution Approach 1:
The patent extracts and measures specific biomarkers (CHI3L1, CRP, EGF, IL6, LEP, MMP1, MMP3, RETN, SAA1, TNFRSF1A, VCAM1, VEGFA) from the complex blood matrix using immunoassays. By focusing on a panel of disease-specific biomarkers rather than general inflammation markers, the system extracts relevant information while filtering out non-specific background interference and rheumatoid factor effects.
Solution Approach 2:
The system uses a composite approach by measuring a panel of 12 different biomarkers simultaneously rather than relying on a single marker. This multi-biomarker panel provides a composite picture of disease activity that is more reliable and specific than any individual biomarker, compensating for limitations of individual markers through their combined information.
3Loss of information
If frequent assessments are performed to track uncoupling of disease activity and progression, then treatment response can be monitored, but time and resources are consumed
Solution Approach 1:
The automated immunoassay system enables continuous monitoring of disease activity by processing samples quickly and generating results rapidly. The system can handle high throughput of samples, allowing frequent assessments without significant time loss, thereby maintaining continuous information about disease activity and treatment response in RA patients.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method offers a more accurate, less invasive, and time-efficient assessment of RA disease activity, capable of predicting radiographic progression and guiding therapy adjustments.
Implementation Method 1
contacting the first blood sample with a plurality of distinct reagents; generating a plurality of distinct complexes between the reagents and markers; and detecting the complexes to generate the data
Data Source
AI summary
Provided herein are methods for assessing response to inflammatory disease therapy. The methods include performing immunoassays to generate scores based on quantitative data for expression of biomarkers relating to inflammatory biomarkers to assess disease activity in inflammatory diseases, e.g., rheumatoid arthritis. Also provided are methods of adjusting disease activity scores to account for variables that can influence such scores.